Announcement PDF ABN 16 165 160 841 ASX RELEASE 11 June 2024 PRESENTATION AND WEBINAR Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to announce that the Company’s CEO and Managing Director Dr Chris Burns is presenting an introduction to the Company as part of a series of webinars hosted by Sharewise. A copy of the slides to be presented is attached. The webinar will commence at 3pm AEST today starting with the presentation followed by a live Q&A with the audience. Shareholders and other interested parties may join the webinar via the following link: https://zoom.us/webinar/register/7517167969965/WN_eofg15bOStGvpm4LKQFJxQ This ASX announcement was approved and authorised for release by the CEO. - End - Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com